SCHEMBL1309734

SCHEMBL1309734

COc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(OC)n1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 15/20 0.59
MTOR P42345 15/20 0.59
PIK3R1 P27986 9/20 0.54
MAPK1 P28482 3/20 0.51
RICTOR Q6R327 2/20 0.49
RPTOR Q8N122 2/20 0.49
MAPKAP1 Q9BPZ7 2/20 0.49
MLST8 Q9BVC4 2/20 0.49
PIK3CD O00329 2/20 0.48
PIK3C2B O00750 2/20 0.48
PIK3CB P42338 2/20 0.48
PIK3CG P48736 2/20 0.48
PIK3C3 Q8NEB9 2/20 0.48
PI4KB Q9UBF8 2/20 0.48
PRKDC P78527 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7999531 0.76 PIK3CA (0.72) PIK3CAMTORPIK3R1RICTORRPTOR
SCHEMBL1311931 0.75 MAPK1 (0.52) PIK3CAMTORPIK3R1MAPK1PIK3CD
SCHEMBL1312053 0.73 PIK3CA (0.57) PIK3CAMTORPIK3R1MAPK1PIK3CD
SCHEMBL4439775 0.73 PIK3CA (0.66) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL17571355 0.72 PIK3CA (0.68) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL1310155 0.72 PIK3CA (0.65) PIK3CAMTORPIK3R1RICTORRPTOR
SCHEMBL1310950 0.72 PIK3CA (0.71) PIK3CAMTORPIK3R1RICTORRPTOR
SCHEMBL8277453 0.71 MAPK1 (0.73) MAPK1SMN1; SMN2
SCHEMBL24920400 0.71 MAPK1 (0.57) PIK3CAMAPK1PIK3CDPIK3CBSMN1; SMN2
SCHEMBL25528429 0.71 PIK3CA (0.49) PIK3CAMTORPIK3R1MAPK1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364302-B1 TRIAZINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIV BASEL (CH) 2016-10-05 EP disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD PIK3CA 2/4885MTOR 1/4885PIK3R1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.